Acro Biomedical Co., Ltd. Sustainability Profile
Acro Biomedical Co., Ltd., headquartered in the United States, is a leading player in the biomedical industry, specialising in innovative medical devices and advanced healthcare solutions. Founded in 2015, the company has rapidly established itself as a key provider of cutting-edge products that enhance patient care and improve clinical outcomes. With a strong operational presence across North America and Europe, Acro Biomedical focuses on developing unique technologies in areas such as regenerative medicine and surgical instruments. Their core offerings, including biocompatible materials and precision-engineered devices, are distinguished by their commitment to quality and efficacy. Recognised for its contributions to the field, Acro Biomedical has achieved significant milestones, positioning itself as a trusted name among healthcare professionals and institutions. The company continues to drive advancements in biomedical technology, ensuring a healthier future for patients worldwide.
DitchCarbon Score
How does Acro Biomedical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acro Biomedical Co., Ltd.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Acro Biomedical Co., Ltd.'s reported carbon emissions
Acro Biomedical Co., Ltd., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Acro Biomedical may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives. In the context of the broader industry, many companies are increasingly adopting science-based targets and participating in initiatives such as the Science Based Targets initiative (SBTi) to align their operations with global climate goals. However, without specific emissions data or commitments, it is unclear how Acro Biomedical is positioning itself in relation to these trends.
How Carbon Intensive is Acro Biomedical Co., Ltd.'s Industry?
How Carbon Intensive is Acro Biomedical Co., Ltd.'s Location?
Acro Biomedical Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Acro Biomedical Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
